The results of the molecular docking simulation above showed that BCL2 tended to be the potential target involved in EGFR-TKI resistance and non-small cell lung cancer pathways and LCA could be an active compound to decrease the EGFR-TKI resistance. The gene discussed is BCL2; the disease is non-small cell lung carcinoma.